Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.
Last year’s FDA draft guidance for the research of psychedelic drugs offered a pathway for research for the biopharmaceutical industry. In The Hill, Precision’s Robert Bauer discusses the challenges to ultimate approval by the FDA.